THE BOOK
 

In this exciting book (Kensington Publishing), Dr. Shamsuddin describes the amazing results of his ground-breaking experiments of the last 20 years, as to how the B-vitamin inositol and its derivative inositol hexaphosphate (IP-6) prevent the formation of cancer and even shrink pre-existing experimental cancers, in clear easy to understand language, yet providing all the scientific data and references for those who would like more details. He also describes the many other fascinating health benefits of these natural products. Learn how IP-6 + Inositol boost immune system, help lower cholesterol, prevent kidney stones and the complications of diabetes and sickle cell anemia, and reduce the risk of cardiovascular diseases, including heart attack and stroke. Also available in Japanese.
 

THE AUTHOR
 

Dr. AbulKalam M. Shamsuddin MD, PhD, is Professor of Pathology at the University of Maryland School of Medicine in Baltimore. Since 1975, he has been researching the processes of cancer formation, cancer prevention and cancer treatment. Inventor of rapid, simple and inexpensive screening tests for cancers of colon, lung, breast [US Patents #4 857 457, #5 162 202 and #5 348 860, and Japanese Patent #2 990 528; he is also the pioneering scientist to demonstrate the immune enhancing and anti-cancer actions of IP-6 & Inositol, for which he was awarded the US patent # 5 082 833, European Patent # 0 422 109, Japanese Patent #3188897 and German Patent # 689 12 331. More recently he has been a co-inventor of additional [pending] patents on a novel IP6-Citrate compound that has even better anti-oxidant properties than IP-6, the use of IP-6 & Inositol in protection against radiation, and the use of IP-6 & Inositol in bone and dental health.
 

LATEST BOOK...
 

This recently-published book updates the information about IP-6 + Inositol. The author Dr. Kim Vanderlinden is a naturopathic physician in Vancouver, Canada who treats patients and is conducting clinical trials with IP-6 + Inositol; Co-author Dr. Ivana Vucenik, a hematologist and an expert in IP-6 & Inositol research is an Associate Professor at the University of Maryland School of Medicine and former Associate Director of Research at the American Institute for Cancer Research in Washington, D.C. In plain, easy to read language, they review the plethora of up-to-date scientific and clinical data on the numerous health benefits of IP-6 + Inositol. Description of the 'road blocks' that came on the way from the discovery to human use and the politics of cancer research makes it an even more interesting reading; please call 1-866-NATURAL (628-8725) for a copy.
 

THE SCIENCE
 

First performed in Dr. Shamsuddin's laboratory, experiments on the anti-cancer action of IP-6 & Inositol have been subsequently reproduced and extended by scientists around the world, reconfirming these fascinating findings. Inositol and IP-6, and the other inositol phosphates i.e. IP-1, IP-2, IP-3, IP-4, IP-5 are normally present in all mammalian cells. IP-3 is a key molecule responsible for cellular signal transduction, controlling vital functions including cell proliferation and differentiation. IP-6 can lose one or more phosphate (P) while inositol can gain them. Thus the combination of IP-6 + Inositol could yield more of the crucial IP-3. The theory is: since i) all cancers, irrespective of their type and origin have a common defect of uncontrolled cell proliferation, ii) IP-3 is a key regulator of cell growth and iii) IP-6 + Inositol yield IP-3, therefore, IP-6 + Inositol should be effective against many a different types of cancers, and across species. The proof can be seen in "About Us" and "What's New." Ongoing research are providing us with new information about these intriguing molecules, almost every day; regulation of p53, p27, ppRb, Akt, PI-3 Kinase, ERK 1/2 etc are some of the pathways by which IP-6/Inositol acts. For the latest research papers please go to MEDLINE on PubMed then key in "ip6" or "inositol hexaphosphate" or "ip6 and cancer" or, you may search under an author's last name.